Showing results (21-30 of 167) with videos related to
Sort By:
Pageof 17
Cancer|March 18, 2015
Differences in the survival of patients with recurrent versus de novo metastatic KRAS-mutant and EGFR-mutant lung adenocarcinomasHelena A Yu, Camelia S Sima, Matthew D Hellmann, et al.Journal for Immunotherapy of Cancer|November 22, 2018
Acquired resistance to immunotherapy in MMR-D pancreatic cancerZishuo Ian Hu, Matthew D Hellmann, Jedd D Wolchok, et al.Lung Cancer (Amsterdam, Netherlands)|June 20, 2017
Prognostic impact of TTF-1 expression in patients with stage IV lung adenocarcinomasJuliana B Schilsky, Ai Ni, Linda Ahn, et al.Oncotargets and Therapy|April 25, 2017
The activity, safety, and evolving role of brigatinib in patients with ALK-rearranged non-small cell lung cancersJoshua K Sabari, Fernando C Santini, Alison M Schram, et al.Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|December 2, 2019
Utilization and factors precluding the initiation of consolidative durvalumab in unresectable stage III non-small cell lung cancerNarek Shaverdian, Michael D Offin, Andreas Rimner, et al.Immunity|January 5, 2022
Germline HLA landscape does not predict efficacy of pembrolizumab monotherapy across solid tumor typesAparna Chhibber, Lingkang Huang, Hong Zhang, et al.Cancer Immunology Research|December 14, 2016
Somatic Mutations and Neoepitope Homology in Melanomas Treated with CTLA-4 BlockadeTavi Nathanson, Arun Ahuja, Alexander Rubinsteyn, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|September 4, 2015
Impact of Concurrent PIK3CA Mutations on Response to EGFR Tyrosine Kinase Inhibition in EGFR-Mutant Lung Cancers and on Prognosis in Oncogene-Driven Lung AdenocarcinomasJuliana Eng, Kaitlin M Woo, Camelia S Sima, et al.Lung Cancer (Amsterdam, Netherlands)|September 18, 2021
Intra- and inter-reader agreement of iRECIST and RECIST 1.1 criteria for the assessment of tumor response in patients receiving checkpoint inhibitor immunotherapy for lung cancerSandra Huicochea Castellanos, Andrew Pagano, Andrew J Plodkowski, et al.International Journal of Cancer|March 7, 2020
Phase 1 study of epacadostat in combination with atezolizumab for patients with previously treated advanced nonsmall cell lung cancerMatthew D Hellmann, Scott Gettinger, Laura Q M Chow, et al.Pageof 17